依帕司他治疗早期2型糖尿病肾病的临床效果研究  

Clinical Effect of Epalrestat in the Treatment of Early Type 2 Diabetic Nephropathy

作　　者：孙燕 SUN Yan(Department of Pharmacy,Hedong District Maternal and Child Health Hospital,Linyi 276000,Shandong,China)

机构地区：[1]临沂市河东区妇幼保健院药剂科,山东临沂276000

出　　处：《糖尿病新世界》2024年第12期183-186,共4页Diabetes New World

摘　　要：目的分析依帕司他治疗早期2型糖尿病肾病(type 2 diabetic nephropathy,DN)的临床效果。方法选取2022年1月—2023年12月临沂市河东区妇幼保健院收治的90例早期DN患者为研究对象,按照治疗方法不同分为对照组和观察组,各45例。对照组采用常规降糖治疗+前列地尔治疗,观察组在对照组基础上联合依帕司他治疗。比较两组治疗总有效率、炎症因子水平(白细胞介素-8、白细胞介素-27、降钙素原)、肾功能(血清尿素氮、血清肌酐)、不良反应(头痛、腹泻、食欲不振)发生情况。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组炎症因子水平比较,差异无统计学意义(P均>0.05);治疗后,两组炎症因子水平均降低,且观察组低于对照组,差异有统计学意义(P均<0.05)。治疗前,两组肾功能指标水平比较,差异无统计学意义(P均>0.05);治疗后,两组肾功能指标水平均降低,且观察组低于对照组,差异有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论依帕司他治疗早期DN效果较好,可以减轻炎症反应,改善肾功能,用药安全性较高。Objective To analyze the clinical effect of epalrestat in the treatment of early type 2 diabetes nephropathy(DN).Methods A total of 90 patients with early DN admitted to Hedong Maternal and Child Health Hospital of Linyi from January 2022 to December 2023 were selected as the research objects.According to different treatment methods,they were divided into the control group and the observation group,with 45 cases in each group.The control group was treated with conventional hypoglycemic therapy+alprostadil,and the observation group was treated with epalrestat on the basis of the control group.The total effective rate of treatment,levels of inflammatory factors(interleukin-8,inter-leukin-27,procalcitonin),renal function(blood urea nitrogen,serum creatinine),and adverse reactions(headache,di-arrhea,loss of appetite)were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).Before treat-ment,there were no statistically significant differences in the levels of inflammatory factors between the two groups(all P>0.05).After treatment,the levels of inflammatory factors in the two groups were decreased,and the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).Before treatment,there were no statistically significant differences in the levels of renal function indexes between the two groups(all P>0.05).After treatment,the renal function index levels of the two groups were decreased,and the observa-tion group were lower than those of the control group,and the differences were statistically significant(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Epalrestat is effective in the treatment of early DN,which can reduce the inflammatory response,improve renal function,and has high drug safety.

关 键 词：依帕司他 早期2型糖尿病肾病 临床疗效 炎症反应 肾功能 

分 类 号：R4[医药卫生—临床医学]